eosinophilic colitis | Rare Diseases Clinical Research Network

Marc Rothenberg, MD, PhD, with a future researcher of eosinophilic disease

CEGIR Researchers Report on the FDA Workshop: Challenges, Progress, Questions in Eosinophilic Gastrointestinal Disorders

January 13, 2022

The U.S. Food and Drug Administration (FDA) hosted a workshop on July 21, 2021 to discuss the disease characteristics, natural history, and endpoints to assess treatment benefit in patients with eosinophilic gastrointestinal disorders (EGID) beyond eosinophilic esophagitis (EoE).

Consortium of Eosinophilic Gastrointestinal Disease Researchers

CEGIR

Eosinophilic gastrointestinal diseases

EGIDS

eosinophilic esophagitis

eosinophilic colitis

Consortia News

eosinophilic gastrities

duodenal eosinophilia

Subscribe to eosinophilic colitis

The Rare Diseases Clinical Research Network (RDCRN) is funded by the National Institutes of Health (NIH) and led by the National Center for Advancing Translational Sciences (NCATS) through its Division of Rare Diseases Research Innovation (DRDRI). The RDCRN websites are hosted by the network’s Data Management and Coordinating Center at Cincinnati Children’s Hospital Medical Center, which is funded by NCATS and the National Institute of Neurological Disorders and Stroke (NINDS) under grant number TR002818.